CAR-T CELL THERAPIES: ADDRESSING KEY UNMET NEEDS ACROSS VARIOUS ONCOLOGICAL INDICATIONS

Amidst the active initiatives undertaken to develop more targeted anti-cancer therapies, CAR-T therapies have emerged as a promising option, given their ability to eradicate tumor cells from the body with minimal treatment-related side effects.

Further, CAR-T cell therapy, a relatively recent addition to the gamut of anticancer interventions, has demonstrated significant promise. Overall, this highly specific and promising form of CAR-T cell therapy treatment, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally. Given the consistent increase in number of cell therapies being developed and launched, this upcoming therapeutic segment is on its way to becoming one of the highest valued markets within the biopharmaceutical industry.


For additional details, please visit https://www.rootsanalysis.com/....reports/view_documen

MANUFACTURING EXECUTION SYSTEM PROVIDERS IN HEALTHCARE MARKET

Every year, the healthcare industry generates a massive amount of data. In fact, the healthcare data currently constitutes around 30% share of the global data volume. Further, it is estimated that, by 2025, the data generated via the healthcare sector will rise at a compound annual growth rate of 36%.

It is important to consider that the constant management of such enormous volumes of data is a quite tedious process and challenging process. Specifically, management and handling of huge datasets in the healthcare industry often requires a large workforce of specialized personnel. According to the American Hospital Association, by 2026, there is likely to be a shortage of 3.2 million healthcare workers. The continuously growing data, coupled to the projected deficit of healthcare workers, would inadvertently generate pressure on healthcare manufacturers to adopt novel tools / technologies that can improve management efficiency and better utilize the available, expensive resources.

For additional details, please visit
https://www.rootsanalysis.com/....reports/manufacturin

THE INTRICACIES ASSOCIATED WITH CELL THERAPY MANUFACTURING HAVE PAVED THE WAY FOR NOVEL AUTOMATION TECHNOLOGIES

Over the years, several advanced and innovative automation tools and technologies have been developed; these have been demonstrated to hold the potential for significant reduction in the cost associated with the manufacturing of advanced therapy medicinal products, thereby, making such products more affordable.

The focus of stakeholders has now shifted to optimizing the cell therapy manufacturing process. It is important to mention that we have forecasted the evolution of the overall cell therapy manufacturing market, focusing on T-cell immunotherapies, dendritic cell therapies, NK cell therapies and stem cell therapies. Considering the sufficient body of evidence vali**** the clinical benefits / therapeutic potential of this complex class of biologic drugs, the focus of stakeholders has now shifted to optimizing the cell therapy manufacturing process.


For additional details, please visit https://www.rootsanalysis.com/....reports/view_documen

The companion diagnostics development services market, is anticipated to grow at a CAGR of over 10%

Given the various challenges associated with co-development of companion diagnostics and drug / therapy, drug developers prefer to rely on third-party service providers that offer customized services and advanced technologies.

The growing pipeline of patient-centric targeted therapies has led to a surge in demand for companion diagnostics; these tests are known to improve the success rates of late-stage trials by almost three-fold. The development and approval of these FDA classified high-risk devices requires multidisciplinary expertise and an established network of R&D and production facilities that can be accessed through service providers.


For additional details, please visit
https://www.rootsanalysis.com/....reports/view_documen

The biopharmaceutical contract manufacturing market is projected to grow at a CAGR of 10% during 2022-2035, claims Roots Analysis

With the advent of novel technologies and rising preference for such therapeutic interventions, biologics have made a significant impact in the pharmaceutical domain, delivering a ground-breaking treatment regimen for a myriad of disease indications.
In pursuit of both time and cost savings, as well as to access higher scales of production, outsourcing has emerged as a lucrative option for biologic drug developers. Driven by several blockbuster products, a burgeoning pipeline of biologic drugs, the demand for reliable contract service providers, which have the required expertise and advanced manufacturing capabilities, is expected to grow at a commendable pace in the coming years. Currently over 275 companies claim to be biopharma CDMO / biopharma CMO, in compliance with the regulatory standards.

For additional details, please visit
https://www.rootsanalysis.com/....reports/view_documen